MedTrace Logo

Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease.

NCT02237820 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-04-06

No results posted yet for this study

Summary

This is the first study assessing the impact of dexamethasone (a glucocorticosteroid with negligible mineralocorticoid activity) as compared to prednisone on short-term outcomes of HF patients hospitalized with exacerbation of COPD. The study may provide important data regarding a simple but potentially robust intervention among large patient population with high rates of hospital admissions.

Conditions

Interventions

DRUG

Dexamethasone

6 mg/day of Oral Dexamethasone

DRUG

Prednisone

40 mg/day of Oral Prednisone

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Gideon Y Stein, MD PhD · Beilinson Hospital, Rabin Medical Center

  • Ran Nissan, PharmD · Beilinson Hospital, Rabin Medical Center

  • Lisa Cooper, MD · Beilinson Hospital, Rabin Medical Center

  • Mordechai R Kramer, MD · Beilinson Hospital, Rabin Medical Center

  • Shmuel Fuchs, MD · Beilinson Hospital, Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2025-05-31
Completion
2025-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237820 on ClinicalTrials.gov